Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia

J. Auer, G. Simon, J. Stevens, P. Griffiths, D. Howarth, E. Anastassiades, R. Gokal, D. Oliver

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Twenty-two continuous ambulatory peritoneal dialysis (CAPD) patients, mean age 48 years, at 3 U.K. renal units were assessed with the Nottingham Health Profile (NHP) before and after treatment with recombinant human erythropoietin (r-HuEPO). Mean (SD) hemoglobin (Hb) at baseline was 7.5 (1.0) gm/dL and 10.8 (1.5) gm/dL at retest. There were significant improvements in energy (p<0.0001), social life (p<0.005), relationships at home (p<0.05) and leisure pursuits (p<0.05). Twelve patients, mean age 51 years, who had already completed more than 9 months on r-HuEPO treatment were reassessed to determine the changes sustained. Mean (SD) Hb at second retest was 12.8 (1.3) gm/dL. Improvement in energy continued to be significant, and emotional wellbeing showed further improvement. Problems with household tasks, which had not shown significant improvement at Test B, were now considerably reduced (p=0.016). The study showed far-reaching benefits similar to those reported in hemodialysis patients, in a population with a higher mean age and higher potential coexisting illness or disability than most reported hemodialysis studies.

Original languageEnglish
Pages (from-to)40-42
Number of pages3
JournalPeritoneal Dialysis International
Volume12
Issue number1
Publication statusPublished - 1992

Keywords

  • Anemia
  • Erythropoietin (subcutaneous)
  • Quality of life

Fingerprint Dive into the research topics of 'Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia'. Together they form a unique fingerprint.

  • Cite this

    Auer, J., Simon, G., Stevens, J., Griffiths, P., Howarth, D., Anastassiades, E., Gokal, R., & Oliver, D. (1992). Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia. Peritoneal Dialysis International, 12(1), 40-42.